Mycophenolate Mofetil for Injection USP, 500 mg/Vial recall — Mylan Pharmaceuticals Inc (Class II)

Mylan Pharmaceuticals Inc is recorded by the U.S. Food and Drug Administration (FDA) as recalling Mycophenolate Mofetil for Injection USP, 500 mg/Vial — a Class II recall, initiated 2026-07-02 and posted to the FDA enforcement report on 2026-08-05, under recall number D-0734-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Presence of precipitate”. From the product description, the form is for injection, the strength given is 500 mg/Vial, the package is described as 4 vials per carton and it is marked Rx only. 2 National Drug Code numbers are printed in the record: 67457-386-00 and 67457-386-81. Distribution is recorded as “USA Nationwide” — Nationwide (US), with the recalling firm on record in WV, United States. It is the only recall number the FDA has filed under event ID 99364. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0734-2026
FDA event ID 99364
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Mylan Pharmaceuticals Inc
Recall initiated 2026-07-02
Reported by FDA 2026-08-05
Report lag 34 days from initiation to report
Distribution USA Nationwide — Nationwide (US)
Firm location on record WV, United States
Product description (source) Mycophenolate Mofetil for Injection USP, 500 mg/Vial, Single Dose Vial, 4 vials per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV, 26505 USA, Made in India, NDC 67457-386-00 (vial label) & NDC 67457-386-81 (carton label).

Reason reported by FDA

Presence of precipitate

3 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

8 identifying values matched by exact pattern in the 37-word product description above; each is a literal substring of it.

Product named Mycophenolate Mofetil for Injection USP
Form for Injection
Strength 500 mg/Vial
Package 4 vials per carton
NDC 67457-386-00 · 67457-386-81
Marketing category Rx only
Stated origin India
Manufactured for Mylan Institutional LLC, Morgantown

Reported in the same month (2026-08)

11 enforcement reports carry a report date in 2026-08; these 4 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, 2%/0.5%D-0730-2026Micro Labs Usa IncClass II2026-08-05
Azelaic Acid Gel, 15%D-0731-2026Glenmark Pharmaceuticals Inc., UsaClass II2026-08-05
Dicyclomine Hydrochloride Capsules, 10mgD-0733-2026Aurobindo Pharma Usa IncClass II2026-08-12
Mirabegron Extended-Release Tablets, 25 mgD-0745-2026Zydus Pharmaceuticals (usa) IncClass II2026-08-12

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 10 nearest to 2026-08-05 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Levothyroxine Sodium Tablets, 25 mcgD-0700-2026Major Pharmaceuticals25 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 50 mcgD-0701-2026Major Pharmaceuticals50 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 75 mcgD-0702-2026Major Pharmaceuticals75 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 88 mcgD-0703-2026Major Pharmaceuticals88 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 112 mcgD-0704-2026Major Pharmaceuticals112 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 125 mcgD-0705-2026Major Pharmaceuticals125 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 150 mcgD-0706-2026Major Pharmaceuticals150 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 25 mcgD-0707-2026Major Pharmaceuticals25 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 50 mcgD-0708-2026Major Pharmaceuticals50 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 75 mcgD-0709-2026Major Pharmaceuticals75 mcg · Tablets2026-07-29

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 67457-386-00 and 67457-386-81 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Mylan Pharmaceuticals Inc (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0734-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0734-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-08-05
Ingested
2026-08-22
Record hash
985def02ed9b64a8

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.